statements

The stock has been placed in Graded Surveillance Measure (GSM) list GSM - 0.

Norris Medicines Ltd.

BSE: 524414

Sector: Services

Industry Group: Commercial Services & Supplies

Industry: Trading & Distributors

15.01+0.0 (+0.07%)

23 Oct, 12:00 AM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

Norris Medicines Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	16.27	7.84	12.25	9.44	8.36	5.64	5.82	8.13	7.60
Cost of Operating Revenue	10.89	5.25	9.41	6.26	3.99	3.23	3.99	4.80	4.69
Gross Profit	5.37	2.59	2.84	3.17	4.37	2.41	1.83	3.34	2.91
Gross Margin	33.0	33.0	23.2	33.6	52.2	42.7	31.5	41.0	38.3
Total Operating Expenses	17.59	10.73	14.66	10.17	8.07	6.39	6.62	7.96	7.60
Operating Profit	-1.33	-2.88	-2.41	-0.73	0.29	-0.76	-0.80	0.17	0.00
Operating Margin	-8.2	-36.8	-19.7	-7.7	3.5	-13.4	-13.7	2.1	-
Financing Income/(Expense) - Net	-0.73	-0.88	-1.63	-1.48	-1.50	-0.37	-0.44	-0.50	-0.39
Profit before Taxes	-2.01	-3.68	-3.99	-2.18	-1.19	-1.10	-1.18	-0.28	-0.37
Income Taxes	-0.33	-0.84	0.97	1.08	0.56	0.09	0.06	-	-
Profit after Tax	-1.68	-2.84	-4.96	-3.26	-1.75	-1.19	-1.24	-0.28	-0.37
PAT Margin	-10.3	-36.2	-40.5	-34.6	-20.9	-21.1	-21.3	-3.5	-4.8
EPS - Basic - ex Extraordinary Items	-1.68	-2.84	-4.96	-3.26	-1.75	-1.19	-1.24	-0.28	-0.37
EPS - Diluted - ex Extraordinary Items	-1.68	-2.84	-4.96	-3.26	-1.75	-1.19	-1.24	-0.28	-0.37
EBIT	-1.33	-2.88	-2.41	-0.73	0.29	-0.76	-0.80	0.17	0.00
EBITDA	-1.33	-2.88	-2.41	-0.73	0.92	-0.18	-0.26	0.66	0.48
EBITDA Margin	-8.2	-36.8	-19.7	-7.7	11.0	-3.3	-4.5	8.2	6.4

Balance Sheet

Abridged

Understanding Balance Sheet

Norris Medicines Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31
	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	7.40	7.44	8.23	4.27	4.92	6.14	6.34	5.81
Long-Term Investments	0.41	0.41	0.38	0.42	0.42	0.43	0.43	0.43
Property Plant & Equipment - Net	8.90	8.25	7.67	7.07	6.47	5.79	5.27	4.79
Total Non-Current Assets	12.98	13.11	11.55	9.92	8.77	8.04	7.47	7.08
Total Assets	20.39	20.56	19.79	14.19	13.69	14.19	13.81	12.89
Total Current Liabilities	8.77	8.04	11.69	6.78	7.70	12.16	10.15	9.53
Long Term Debt	11.24	14.98	15.52	18.10	18.43	18.59	18.53	18.51
Total Non-Current Liabilities	11.24	14.98	15.52	18.10	18.43	18.59	18.53	18.51
Total Liabilities	20.01	23.02	27.22	24.88	26.13	30.75	28.68	28.04
Total Shareholders' Equity	0.37	-2.47	-7.43	-10.69	-12.44	-13.63	-14.87	-15.15
Total Equity	0.37	-2.47	-7.43	-10.69	-12.44	-13.63	-14.87	-15.15
Total Liabilities & Equity	20.39	20.56	19.79	14.19	13.69	17.12	13.81	12.89

Cash Flow

Abridged

Understanding Cash Flow Statement

Norris Medicines Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	-1.32	-2.98	-3.34	-1.54	-0.58	-0.52	-0.64	0.21
Working Capital - Increase/(Decrease)	-1.33	-0.79	2.82	-0.95	0.27	0.32	0.73	-0.11
Net CF from Operating Activities	-2.64	-3.77	-0.52	-2.49	-0.30	-0.20	0.09	0.10
Capital Expenditures - Net	0.29	0.08	0.09	0.06	0.03	-0.09	0.02	0.01
Net CF from Investing Activities	-0.29	0.00	-0.06	-0.09	-0.02	0.05	-0.02	-0.10
Debt - LT & ST - Issuance/(Retirement) - Total	2.91	3.74	0.54	2.58	0.32	0.17	-0.06	-0.02
Net Cash Flow from Financing Activities	2.91	3.74	0.54	2.58	0.32	0.17	-0.06	-0.02
Free Cash Flow to Equity	-0.03	-0.10	-0.07	0.03	-0.01	0.06	0.01	0.07
Free Operating CF net dividend	-2.93	-3.84	-0.61	-2.55	-0.33	-0.20	0.07	0.09
Free Operating CF	-2.93	-3.84	-0.61	-2.55	-0.33	-0.20	0.07	0.09

Business Segment Analysis

FY End:

Mar 25

Norris Medicines Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Health care (100.0%)₹ 0.02 Cr

Revenue / Sales

Health care (100.0%)₹ 5.82 Cr

Assets

Health care (100.0%)₹ 13.81 Cr

Operating Income

Health care (100.0%)₹ -0.80 Cr

Regional Segment Analysis

Norris Medicines Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Norris Medicines Ltd.

Historical Segment Analysis

Track how Norris Medicines Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2025 Mar 31
	2025 Mar 31
Health care	0

Frequently Asked Questions

What is the revenue of Norris Medicines Ltd.?

The latest trailing twelve month revenue of Norris Medicines Ltd. is ₹ 7.60 Cr, reflecting a 1-year growth of 16.00% and a 3-year CAGR of -4.10%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Norris Medicines Ltd.?

The latest trailing twelve month net profit (PAT) of Norris Medicines Ltd. is ₹ -0.37 Cr, with a 3-year earnings CAGR of 41.40%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Norris Medicines Ltd.?

The trailing twelve month EBITDA of Norris Medicines Ltd. is approximately ₹ 0.00 Cr (based on an operating margin of 0.00%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Norris Medicines Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Norris Medicines Ltd. is -0.37. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Norris Medicines Ltd.?

The debt-to-equity ratio of Norris Medicines Ltd. stands at -. The interest coverage ratio is 0.00x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Norris Medicines Ltd.?

The book value per share of Norris Medicines Ltd. is available in the Balance Sheet section of the Statements tab.

What is the cash flow from operations of Norris Medicines Ltd.?

The trailing twelve month operating cash flow of Norris Medicines Ltd. is ₹ 0.10 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Norris Medicines Ltd. report consolidated or standalone financials?

Norris Medicines Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.